Om

Vogenx Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for serious metabolic and gastrointestinal disorders. Its current work centers on treatments for post-bariatric hypoglycemia and gastroparesis, with additional research in related rare metabolic conditions. The company’s lead program is mizagliflozin, an oral small-molecule SGLT1 inhibitor designed to address abnormal glucose absorption and other metabolic pathways in the gut. Vogenx also maintains a broader pipeline that includes additional drug candidates under evaluation for metabolic disease indications. The company serves the life sciences and drug development market, where it advances investigational therapies aimed at conditions with limited treatment options. Vogenx Inc. is headquartered in Raleigh, North Carolina and operates as a focused developer of novel medicines for metabolic and gastrointestinal disease areas.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I VOGENX MED ENDAVU: Køb Vogenx ($VOGX) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Vogenx, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.